Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
SGLT-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) are commonly used to treat type 2 diabetes mellitus (T2DM), with growing evidence of their kidney-protective effects. However, direct comparisons are limited, and varying definitions of renal outcomes across studies may influence interpretation. We performed a two-step meta-analysis and subgroup network meta-analysis (NMA) to assess their relative effectiveness in preventing kidney disease progression
Eleven randomized controlled trials (RCTs) involving adults with T2DM and chronic kidney disease (CKD) were included. In Step 1, we conducted a naïve random-effects meta-analysis, pooling hazard ratios (HRs) separately for SGLT2i and GLP-1 RAs. In Step 2, we applied a frequentist network meta-analysis (NMA) using the netmeta R package, with placebo as the common comparator. Heterogeneity was evaluated using Cochran’s Q and τ². I² was not reported due to known limitations in sparse networks. A prespecified subgroup analysis was then conducted, restricting to trials using a standardized renal composite outcome (≥40–50% eGFR decline, end-stage kidney disease (ESKD), or renal death).
Step 1 (Naïve Meta-analysis):SGLT2i significantly reduced the risk of renal outcomes compared to placebo (HR = 0.70 [95% CI: 0.66–0.75]), as did GLP-1 RA (HR = 0.78 [95% CI: 0.73–0.83]).
Step 2 (Network Meta-analysis):SGLT2i were significantly more effective than GLP1-RA (HR = 0.90 [95% CI: 0.83–0.98], p = 0.021) and ranked highest based on P-score (0.995). GLP1-RA were also superior to placebo (HR = 0.78 [95% CI: 0.73–0.83]). Between-study heterogeneity was low (Q = 9.62, τ² = 0.0003).
Subgroup NMA (Standardised Renal Composite Trials Only, n = 5):Both SGLT2i and GLP1-RA remained superior to placebo (HR = 0.69 and 0.74, respectively). However, the direct comparison between SGLT2i and GLP1-RA was not statistically significant (HR = 0.93 [95% CI: 0.81–1.07], p = 0.301). Heterogeneity remained negligible (Q = 2.46, τ² = 0).
Both SGLT-2 inhibitors and GLP-1 receptor agonists reduce renal risk in patients with T2DM and CKD. While the overall network analysis suggests superior efficacy with SGLT2i, this distinction diminished in a subgroup of trials using standardised renal endpoints. These findings highlight the importance of harmonised outcome definitions in clinical trials and support the continued prioritisation of SGLT2i for renoprotection.
